Tag: AKB-4924

June 25, 2018

Aerpio and Gossamer Bio Announce License Agreement

The agreement could bring sales milestones of Aerpio up to US$400 million, including US$20 million as an upfront payment, potential...
June 25, 2018

Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924

Aerpio Pharmaceuticals (OTCQB:ARPO), announced an exclusive global license agreement with a wholly owned subsidiary of Gossamer Bio, GB004, for the...